Mikozis Fungoides ve Hemşirelik Yönetimi

Yıl 2019, Cilt: 35 Sayı: 1, 29 - 35, 30.04.2019

İsmail Toygar , Asiye Akyol

Öz

Mikozis Fungoides ve Hemşirelik
Yönetimi

Özet

                Mikozis
fungoides (MF) toplumda yaygın olarak görülen kutanöz T hücreli lenfoma (KTHL)
tipidir. MF tüm KTHL olgularının %73’ünü oluşturmaktadır. MF ülkemizde ve
dünyada sık karşılaşılan sağlık problemleri arasında yer almaktadır. MF
hastaları klinik olarak 4 evrede ele alınmaktadır. Bu evreler sırası ile
premikotik evre, yama evresi, plak evresi ve tümör evresidir. Erken evrelerde
MF ayırıcı tanısı oldukça zordur. MF hastalarının tedavisi lokal deri
uygulamaları ve sistemik uygulamalar olarak iki başlık altında gruplandırılmaktadır.
Erken evre hastalarda yalnızca lokal deri uygulamaları tam remisyon sağlar
iken, ileri evre hastalarda sistemik tedaviler de kullanılmalıdır. Hastaların
şikâyetleri arasında kızarıklık, kuruluk, ağrı ve enfeksiyon ilk sırayı alırken
bunları psikiyatrik ve sosyal sorunlar izlemektedir. MF hastalarının hemşirelik
yönetiminde hasta ile işbirlikçi bir yaklaşım yürütülmesi ve semptomların etkin
kontrolünün sağlanması yer almaktadır. MF hastalarının semptom kontrolünde
kızarıklık, kuruluk, kaşıntı, ağrı, enfeksiyon ve psikiyatrik problemler hedef
alınmalıdır. MF hastalarının etkin tedavi ve bakım ile şikâyetleri
azaltılabilmekte ve ortadan kaldırılabilmektedir. Bu makalede, MF’in tanım,
epidemiyoloji, tanı kriterleri, tedavi ve hemşirelik yönetimi ele alınmıştır.

Anahtar
Kelimeler: Mikozis Fungoides,
Hemşirelik Yönetimi, Bakım.

Mycosis Fungoides and Nursing
Management

Abstract

Mycosis Fungoides (MF), common in community, is a type
of Cutaneous T-Cell Lymphoma (CTCL). MF is 73% of all CTCL case. MF is among
the common health problems in our country and in the world. MF patients
clinically classified in four phases. This phases are premycotic phase, patch
phase, plaque phase and tumor phase respectively. In the early stages, the MF
differential diagnosis is difficult. MF patients’ treatment is grouped as local
skin therapy and systemic therapy. While the early stages of MF, lokal skin
therapy provide complete remission, the advanced stages of MF, systemic therapy
should be used. While patients primarily  suffer from rash, dryness, pain and infection;
psychiatric and social problems follow this symptoms. Nursing management of MF
patients include collaborative approach and effective symptoms management. With
effective treatment and care, MF patients’ suffers may be reduced and removed. Rash,
itching dryness, pain and infection, and psychiatric problems should be
targeted in symptom control of MF patients. In this article definition,
epidemiology, diagnostic criteria, classification, treatment and nursing
management of MF is discussed.

Key
Words: Mycosis Fungoides,
Nursing Management, Care.

Anahtar Kelimeler

Mikozis Fungoides, Hemşirelik Yönetimi, Bakım

Kaynakça

• Alberti-Violetti S, Talpur R, Schlichte M, Sui D, Duvic M. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. Clinical Lymphoma Myeloma and Leukemia. 2015;15(6):105-12.
• Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T‐cell lymphoma on patients' quality of life. Cancer. 2006;107(10):2504-2511.
• Diederen PV, Van Weelden H, Sanders CJ, Toonstra J, Van Vloten WA. Narrowband. UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. Journal of the American Academy of Dermatology. 2003;48(2):215-9.
• Engin B, Bairamov O, Kutlubay Z, Tüzün Y. Mikozis Fungoidesde Tedavi Yaklaşımları. Dermatoz. 2013;4(1):35-9.
• Hoppe RT. Mycosis fungoides: radiation therapy. Dermatologic therapy. 2003;16(4):347-54.
• Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. The Lancet. 2008;371(9616):945-57.
• Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. Journal of the American Academy of Dermatology. 2014;70(2):223-e1.
• Jumbou O, N'guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. British Journal of Dermatology. 1999;140:427-31.
• Kessler J, Levine N, Meyskens F, Lynch P, Jones S. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. The Lancet, 1983;321(8338):1345-7.
• Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Archives of Dermatology. 2003;139(2):165-173.
• McCann SA. Cutaneous T-cell lymphoma: Overview and nursing perspectives. Nursing Clinics, 2007; 42(3): 421-455.
• Mccann SA, Chase AB, Tawa MC. Gelling Your Dermatology Nursing Practice: A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. Journal of the Dermatology Nurses' Association. 2016;8(3):180-192.
• National Cancer Institute (Ncı) (01.06.2018), Mycosis Fungoides Treatment, Erişim: 30.11.2017. http://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq
• Olek-Hrab K, Silny W. Diagnostics in mycosis fungoides and Sezary syndrome. Reports of Practical Oncology & Radiotherapy. 2014;19(2):72-6.
• Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-22.
• Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, Et Al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. European Journal of Cancer. 2006;42(8):1014-1030.
• Vonderheid EC. Treatment planning in cutaneous T‐Cell lymphoma. Dermatologic Therapy. 2003;16(4):276-82.
• Whittaker S, Hoppe R, Prince HM. How we treat mycosis fungoides and sezary syndrome. Blood. 2016;blood-2015.
• Willemze R,Jlm Meijer C. Classification of cutaneous T‐cell lymphoma: from Alibert to WHO‐EORTC. Journal of cutaneous pathology. 2006;33(s1):18-26.
• Wilson LD, Jones GW, Kim D, Rosenthal D, Christensen IR, Edelson RL, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. Journal of the American Academy of Dermatology. 2000;43(1):54-60.
• Zackheim Hs, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Archives of Dermatology. 1998:134(8):949-54.
• Zinzani PL, Ferreri AJ, Cerroni, L. Mycosis fungoides. Critical Reviews in Oncology/Hematology. 2008;65(2):172-82.